| 4.28 0.105 (2.51%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.36 | 1-year : | 6.26 |
| Resists | First : | 4.59 | Second : | 5.36 |
| Pivot price | 4  |
|||
| Supports | First : | 3.97 | Second : | 3.59 |
| MAs | MA(5) : | 4.14 |
MA(20) : | 3.95 |
| MA(100) : | 3.84 |
MA(250) : | 4.12 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 74.9 |
D(3) : | 77.3 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 8.26 | Low : | 0.45 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ATHA ] has closed below upper band by 30.9%. Bollinger Bands are 0.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.51 - 4.53 | 4.53 - 4.55 |
| Low: | 4.09 - 4.12 | 4.12 - 4.14 |
| Close: | 4.13 - 4.17 | 4.17 - 4.21 |
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Fri, 03 Oct 2025
Athira Pharma regains Nasdaq compliance after meeting minimum bid requirement - Investing.com
Thu, 11 Sep 2025
Athira Pharma Announces 10-for-1 Reverse Stock Split - TipRanks
Thu, 11 Sep 2025
Athira Pharma Announces 10-for-1 Reverse Stock Split - Nasdaq
Thu, 11 Sep 2025
Athira Pharma Announces Reverse Stock Split - GlobeNewswire
Thu, 14 Aug 2025
Athira Pharma reports positive Phase 1 results for ALS drug candidate - Investing.com
Thu, 14 Aug 2025
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nex - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 7.7 (%) |
| Held by Institutions | 44.3 (%) |
| Shares Short | 67 (K) |
| Shares Short P.Month | 96 (K) |
| EPS | -15.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -49.3 % |
| Return on Equity (ttm) | -103.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -14.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -0.28 |
| PEG Ratio | 0 |
| Price to Book value | 0.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|